Therapeutic Control of the Immune system

1
Therapeutic Control of the Immune system
2
December 2004
3
Corporate Profile Mission

• Private RD focused Immunology company with
  proprietary product candidates addressing large
  markets with unmet needs
• Targeting regulatory pathways to restore balance
  to the immune system in conditions associated
  with abnormal and harmful immune responses

4
Trillium Today

• Operating in 10,000 sq. ft. fully equipped RD
  facility in Toronto
• Staff 14
• 5 RD Programs
• Recently closed 13.5M Series A Financing

5
Corporate Strengths

• Strong and innovative science
• Proof-of-principle in vivo data
• Multiple product opportunities in large markets
• World class academic and industry RD
  collaborators
• Comprehensive patent portfolio
• Experienced and committed leadership

6
Trilliums Drug Development Process
Clinical Development
Research
Development (IND-enabling)
Early
Late
Development Assessment
7
Five Scientific Programs

• Late Research/Early Development
• 1. CD200Fc (Autoimmunity Transplantation)
• 2. IL-1R Antagonist (Inflammatory disease)
• Early to Mid Research
• 3. CD200 Mab (Cancer and Chronic Viral Disease)
• 4. FGL-2 Mab (Hepatitis)
• 5. IL-18R Antagonist (Inflammatory disease)

8
Market Opportunity gt 20 Billion

• Diabetes
• Rheumatoid Arthritis
• Psoriasis
• Inflammatory Bowel Disease
• Multiple Sclerosis
• Acute Graft Rejection
• Myocarditis

• HIV
• Viral Hepatitis
• Cancer
• Nephritis
• Allergies
• Lupus
• Eczema/Dermatitis

9
Management Team

• Niclas Stiernholm, Ph.D. Chief Executive Officer
• (Allelix, YM Biosciences)
• Bob Uger, Ph.D. Vice President, RD
• (Aventis Pasteur)
• Scott Duncan, B.Sc. Director, Patents
  Licensing
• (Allelix)
• James Parsons, CA Director, Finance Admin.
• (Lorus Therapeutics)

10
Board of Directors

• Calvin Stiller, MD (Chair)
• Chairman, Ontario Research and Development Fund
  Canadian Medical Discoveries Fund
• Brian Underdown, Ph.D.
• Managing Director, Science and Technology, MDS
  Capital Corp.
• Niclas Stiernholm, Ph.D.
• TTI CEO
• Robert Hall, M.B.A.
• Director, Venture Capital Division, Business
  Development Bank of Canada

• Julia Levy, Ph.D.
• Founder and Executive Chairman, Scientific
  Advisory Board, QLT Inc.
• Michael Moore, Ph.D. D.Sc.
• Chief Executive Officer, PIramed Ltd.
• Gary Levy, M.D.
• TTI Founding Scientist Representative
• Elizabeth Corsi, Pharm D.
• President Chief Executive Officer, Eximias
  Pharmaceutical Corporation

11
Scientific Advisory Board

• G. Levy, M.D. (Chair)
• Director, Multi-Organ Transplant Program at The
  Toronto Hospital and CIHR Group in Immunology and
  Transplantation
• M. Sayegh, M.D.
• Director of Research, Immunogenetics and
  Transplantation, Brigham and Womens Hospital,
  Boston
• B. Barber, Ph.D.
• Executive Vice President, University Health
  Network Global Ventures
• V. Kuchroo, DVM, Ph.D.
• Associate Professor of Neurology, Harvard
  Medical School, Boston
• M. Feldmann, M.D., Ph.D.
• Professor, Head Kennedy Institute of
  Rheumatology, Imperial College London, UK

12
Capitalization

• 13.5 M Series A financing (2004)
• Vengrowth Capital Partners
• Canadian Medical Discoveries Fund
• Business Development Bank of Canada
• 250 K Seed financing (1998)
• University Medical Discoveries Inc.
• 4.8 M Contract research (1996-2001)

13
Corporate Strengths

• Strong and innovative science
• Proof-of-principle in vivo data
• Multiple product opportunities in large markets
• World class academic and industry RD
  collaborators
• Comprehensive patent portfolio
• Experienced and committed leadership

14
Contacts
Niclas Stiernholm, PhD Chief Executive
Officer Tel [phone] x222 niclas_at_trilliumthe
rapeutics.com
Bob Uger, PhD Vice President, RD Tel
416-595-0627 x260 bob_at_trilliumtherapeutics.com
96 Skyway Avenue Toronto, Ontario, M9W 4Y9 CANADA